Serina Therapeutics (SER) Total Liabilities (2017 - 2026)

Serina Therapeutics has disclosed Total Liabilities across 10 years of filings, most recently posting $7.1 million for Q2 2026.

• In Q2 2026, Total Liabilities fell 2.89% year-over-year to $7.1 million; the TTM figure through Jun 2026 stood at $7.1 million (down 2.89% YoY), while the FY2025 annual figure was $7.0 million, up 12.42% from the prior year.
• Total Liabilities came in at $7.1 million for Q2 2026 at Serina Therapeutics, up from $7.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $34.6 million in Q2 2023 to a low of $3.9 million in Q3 2023.
• Average Total Liabilities over 5 years is $14.8 million, with a median of $14.3 million recorded in 2022.
• Year-over-year, Total Liabilities tumbled 77.29% in 2023 and soared 445.62% in 2024.
• Over 5 years, Total Liabilities stood at $20.6 million in 2022, then sank by 76.37% to $4.9 million in 2023, then climbed by 27.95% to $6.2 million in 2024, then grew by 12.42% to $7.0 million in 2025, then rose by 1.37% to $7.1 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $7.1 million in Q2 2026, $7.0 million in Q4 2025, and $10.8 million in Q3 2025.